4. Winner: Baxter

Company: Baxter International
Symbol: $BAX
Beginning price: $50.54
Ending price: $68.81
Gain: 36.15%

Baxter International ($BAX) has had issues with infusion pumps, but its drug business--which accounts for about half its revenues--remains solid. It also had about $3 billion in cash sitting on its balance sheet in September, Bloomberg reported. Its share price spiked even higher recently after a rumor surfaced that it was about to spend $4 billion to buy Gambro, one of its key competitors in the kidney dialysis business. If approved, it would round out Baxter's offerings, allow it to cut some costs and remove a competitor from the market.

For more:
Baxter posts Q3 growth, but device sales slide
Report: Baxter close to paying $4B for dialysis rival Gambro
 

4. Winner: Baxter
Read more on

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.